ZLNA ZELLUNA ASA

Zelluna ASA – Key information relating to subsequent offering

Zelluna ASA – Key information relating to subsequent offering

Reference is made to the stock exchange announcement made by Zelluna ASA (the "Company") on 3 November 2025 regarding the allocation of 5,500,000 new shares in the Company in a private placement (the "Private Placement"), the allocation of 315,639 new shares in a retail offering via the PrimaryBid platform (the "PrimaryBid Offering"), and a potential subsequent repair offering of up to 800,000 new shares at the same subscription price as in the Private Placement and the PrimaryBid Offering (the "Subsequent Offering"). The Subsequent Offering will, subject to applicable securities law, be directed towards existing shareholders in the Company as of 3 November 2025, as registered in the Company's register of shareholders with Euronext Securities Oslo on 5 November 2025, who (i) were not included in the pre-sounding phase of the Private Placement; (ii) were not allocated shares in the Private Placement, and (iii) are not resident in a jurisdiction where such offering would be unlawful or, would (in jurisdictions other than Norway) require a prospectus, filing registration or similar action.

The following key information is provided with respect to the Subsequent Offering:

Date on which the terms and conditions of the Subsequent Offering were announced: 3 November 2025

Last day including right: 3 November 2025

Ex-date: 4 November 2025

Record date: 5 November 2025

Date of approval: On or about 25 November 2025 (date of extraordinary general meeting)

Maximum number of new shares: 800,000

Subscription price: NOK 10 per share

Shall the rights be listed: No

Other information: The Subsequent Offering is subject to, inter alia, completion of the Private Placement, approval by the board of directors and an extraordinary general meeting of the Company, and the publication of a prospectus. Whether or not the Subsequent Offering will ultimately take place, will depend inter alia on the development of the price of the shares in the Company after completion of the Private Placement, and the Company reserves the right in its sole discretion to not conduct or to cancel the Subsequent Offering.

This information is published in accordance with the requirements of the Continuing Obligations for Euronext Oslo Børs.



 



EN
03/11/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ZELLUNA ASA

 PRESS RELEASE

Zelluna Receives UK MHRA and Ethics Approval to Initiate ZIMA-101 Firs...

Zelluna Receives UK MHRA and Ethics Approval to Initiate ZIMA-101 First-in-Human Clinical Trial Regulatory clearance enables start of clinical testing and marks transition to clinical-stage companyOn track for initial clinical data to emerge from mid-2026 Oslo, Norway, 20 February 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) and Research Ethics Committee (REC) has approved the Comp...

 PRESS RELEASE

Zelluna mottar UK MHRA og etisk godkjenning for oppstart av ZIMA-101 f...

Zelluna mottar UK MHRA og etisk godkjenning for oppstart av ZIMA-101 første-i-menneske klinisk studie Regulatorisk godkjenning muliggjør oppstart av klinisk testing og markerer overgang til klinisk faseFørste kliniske data forventes fra medio 2026 Oslo, Norge, 20 februar 2026 – Zelluna (OSE: ZLNA) utvikler allogene "off-the-shelf" T-cellereseptor-baserte naturlige dreperceller (TCR-NK) for behandling av solide kreftformer. Selskapet kunngjør i dag at Medicines and Healthcare products Regulatory Agency (MHRA) og Research Ethics Committee (REC) i Storbritannia har godkjent selskapets søkna...

 PRESS RELEASE

Zelluna ASA: Fourth Quarter 2025 – Key regulatory milestone achieved w...

Zelluna ASA: Fourth Quarter 2025 – Key regulatory milestone achieved with CTA Submission Oslo, 12 February 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today presents its results for the fourth quarter and full year 2025. Webcast scheduled for 12 February 2026, at 08:30 (CET). Link to webcast . Operational Highlights Q4 2025 CTA submitted: On 17 December 2025, Zelluna submitted its first Clinical Trial Application (CTA) to the UK MHRA for ZI-MA4-1, the world's ...

 PRESS RELEASE

Zelluna ASA: Fjerde kvartal 2025 – Viktig regulatorisk milepæl oppnådd...

Zelluna ASA: Fjerde kvartal 2025 – Viktig regulatorisk milepæl oppnådd med CTA-innlevering Oslo, 12. februar 2026 – Zelluna (OSE: ZLNA), et selskap som utvikler allogene "off-the-shelf" T-cellereseptor-baserte Natural Killer (TCR-NK) celleterapier for behandling av kreft, presenterer i dag resultatene for fjerde kvartal og året 2025. Webcast er planlagt 12. februar 2026 kl. 08:30 (CET). Lenke til webcast . Operasjonelle høydepunkter Q4 2025: CTA innlevert: 17. desember 2025 leverte Zelluna sin første søknad om oppstart av klinisk studie (Clinical Trial Application, CTA) til UK MH...

 PRESS RELEASE

Zelluna selects Medpace as CRO for ZIMA-101 first-in-human clinical tr...

Zelluna selects Medpace as CRO for ZIMA-101 first-in-human clinical trial Global CRO to support execution of ZIMA-101 study with world's first MAGE-A4-targeting TCR-NK cell therapy productPartnership follows submission of the Clinical Trial Application (CTA) to the MHRA Oslo, Norway – 11 February 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today announced a clinical partnership with Medpace, a leading global Contract Research Organization (CRO), to support the f...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch